BOUNDLESS BIO INC SEC Filings

Boundless Bio, Inc. (NASDAQ: BOLD) filed a Form 4 disclosing that director James Christensen received a new stock-option grant on 06/23/2025. The award covers 16,000 options with an exercise price of $1.03 per common share and an expiration date of 06/22/2035. The option vests in substantially equal monthly installments over the 12 months following the grant date. Any unvested portion will accelerate and vest on the date of the company’s next annual shareholder meeting if that meeting occurs before 06/23/2026, provided the director remains on the board.

The filing shows that these options represent the entirety of Christensen’s reported derivative holdings after the transaction; no open-market purchases, sales, or other equity awards were reported. Ownership is listed as direct, indicating the director personally holds the options rather than through a trust or other entity. No non-derivative (common-stock) transactions were disclosed.

Because the filing reports a routine board compensation grant rather than a discretionary insider purchase or sale, it is typically regarded as a neutral governance event for valuation purposes. There is no accompanying financial guidance, earnings data, or indication of broader corporate actions.

Director Jennifer Lew of Boundless Bio received a stock option grant on June 23, 2025. The grant consists of options to purchase 16,000 shares of common stock at an exercise price of $1.03 per share.

Key details of the stock option grant:

• Exercise price: $1.03 per share
• Expiration date: June 22, 2035
• Vesting schedule: Monthly installments over 12 months through June 23, 2026
• Accelerated vesting provision: Any unvested portion will vest at next annual stockholder meeting if occurring before June 23, 2026
• Vesting contingent on continued board service

The Form 4 was filed by Jessica Oien as attorney-in-fact for Jennifer Lew, reporting a direct ownership form of the derivative securities.

Director Jonathan E. Lim of Boundless Bio received a stock option grant on June 23, 2025, representing a significant insider transaction. The key details include:

• Granted 24,000 stock options to purchase common stock
• Exercise price set at $1.03 per share
• Options expire on June 22, 2035
• Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
• Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026

The grant was executed under direct ownership, with Jessica Oien signing as attorney-in-fact. This equity compensation aligns with standard director compensation practices and demonstrates the company's commitment to retaining board talent through long-term incentives.

Form 4 Overview: On 06/23/2025, Boundless Bio, Inc. (ticker BOLD) filed a Form 4 disclosing a grant of derivative securities to director and 10% owner Kristina Burow.

• Security granted: Stock option (right to buy)
• Quantity: 16,000 options
• Exercise price: $1.03 per share
• Vesting schedule: Monthly over 12 months beginning 06/23/2025; any unvested portion accelerates to the next annual shareholder meeting if earlier.
• Expiration: 06/22/2035
• Ownership form after transaction: Direct (16,000 derivative securities)

No non-derivative share transactions were reported. The filing represents routine director compensation rather than an open-market purchase, and it does not include financial performance metrics or earnings data.

Boundless Bio director Nancy Whiting received a stock option grant on June 23, 2025, according to a Form 4 filing. The key details of the transaction include:

• Granted 16,000 stock options to purchase common stock
• Exercise price set at $1.03 per share
• Options expire on June 22, 2035
• Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
• Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026

The options were granted as part of director compensation and are subject to continued service on the company's board. The transaction was executed under direct ownership, with Jessica Oien signing as attorney-in-fact for Nancy Whiting.

Boundless Bio, Inc. (Nasdaq: BOLD) filed a Form 8-K detailing the results of its 23 June 2025 annual meeting of stockholders.

• Director elections: Class I nominees Christine Brennan, Ph.D. (9,252,440 for / 5,046,258 withheld) and Nancy Whiting, Pharm.D. (9,758,214 for / 4,540,484 withheld) were elected to serve until the 2028 annual meeting; 3,540,518 broker non-votes were recorded for each candidate.
• Auditor ratification: Shareholders ratified KPMG LLP as independent registered public accounting firm for fiscal 2025 with 17,791,309 votes for, 47,807 against and 100 abstentions.

No other matters were brought before shareholders and no additional material disclosures were made.